🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

635 results for “dose” Clear

  1. Four naloxone nasal spray doses (1 every 2.5 min)

    BRIGHT MINDS BIOSCIENCES INC.

    Healthy Subjects

    phase 1 small molecule completed

    1 trial

  2. GLPG1205 single ascending doses, oral suspension

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  3. GLPG1690 single ascending doses

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  4. GLPG1837 single ascending doses

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  5. GLPG1972 single ascending doses

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  6. GLPG2222 single dose

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  7. GLPG2451 dose regimen A

    Lakefront Biotherapeutics NV

    Cystic Fibrosis

    phase 1 small molecule completed

    1 trial

  8. GLPG2451 multiple dose

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  9. GLPG2451 single dose

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  10. GLPG2737 single dose

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  11. GLPG2737 single dose

    Lakefront Biotherapeutics NV

    Cystic Fibrosis

    phase 1 small molecule completed

    1 trial

  12. GLPG3067 single dose

    Lakefront Biotherapeutics NV

    Cystic Fibrosis

    phase 1 small molecule completed

    1 trial

  13. GLPG3067 single dose

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  14. GRT-1C102: A randomized, double-blind, placebo-controlled dose escalation study to evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics of GRT-001 after subcutaneous administrations to healthy subjects (MONOSqut trial).

    Rani Therapeutics Holdings

    Ulcerative colitis

    phase 1 other active

    1 trial

  15. GTX-102 medium dose fast Period 1 and Period 2

    Grace Therapeutics

    Ataxia Telangiectasia

    phase 1 small molecule active

    1 trial

  16. HS-10382(Part 1: Dose escalation)

    Jian Li

    CML, Chronic Phase

    phase 1 small molecule active

    1 trial

  17. IMC-I109V Single Ascending Dose

    Immunocore Ireland Limited

    Hepatitis B, Chronic

    phase 1 small molecule terminated

    1 trial

  18. INTERACT MESO: Intraperitoneal Paclitaxel for Patients with Primary Malignant Peritoneal Mesothelioma – a Phase I/II Dose Escalation and Safety Study

    Disc Medicine

    Patients with malignant peritoneal mesothelioma

    phase 1 other active

    1 trial

  19. INV21 Low Dose

    Takeda

    Hand, Foot and Mouth Disease

    phase 1 mab completed

    1 trial

  20. ITI-214 Dose A

    Takeda

    Schizophrenia

    phase 1 small molecule terminated

    1 trial

  21. Investigation of pharmacokinetics, safety and tolerability of a single subcutaneous dose of NNC0487-0111 in participants with various degrees of renal impairment and normal renal function.

    NovoThirteen

    Obesity and Diabetes mellitus Typ 2

    phase 1 other active

    1 trial

  22. Ketamine (Ketalar) Dose Level 1

    Grace Therapeutics

    Pain, Postoperative

    phase 1 small molecule completed

    1 trial

  23. Liposomal Mitoxantrone Hydrochloride dose level 1

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non Hodgkin Lymphoma

    phase 1 small molecule active

    1 trial

  24. Low Dose MSH2-/- tumor cell vaccine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    pMMR/MSS Advanced Colorectal Cancer

    phase 1 mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources